Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus

Daniel Q Holland, Joshua J NeumillerDepartment of Pharmacotherapy, College of Pharmacy, Washington State University, Spokane, Washington, USAAbstract: Alogliptin is a selective dipeptidyl peptidase-4 inhibitor recently marketed for once-daily administration in the treatment of type 2 diabetes melli...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Holl, DQ, Neumiller JJ
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/53402642e95245d494c8940a9115b18a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:53402642e95245d494c8940a9115b18a
record_format	dspace
spelling	oai:doaj.org-article:53402642e95245d494c8940a9115b18a2021-12-02T04:12:03ZAlogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus1178-7007https://doaj.org/article/53402642e95245d494c8940a9115b18a2014-07-01T00:00:00Zhttp://www.dovepress.com/alogliptin-in-combination-with-metformin-and-pioglitazone-for-the-trea-a17455https://doaj.org/toc/1178-7007 Daniel Q Holland, Joshua J NeumillerDepartment of Pharmacotherapy, College of Pharmacy, Washington State University, Spokane, Washington, USAAbstract: Alogliptin is a selective dipeptidyl peptidase-4 inhibitor recently marketed for once-daily administration in the treatment of type 2 diabetes mellitus (T2DM). Fixed-dose combinations of alogliptin with both metformin and pioglitazone are also commercially available, providing a measure of convenience in addition to an effective mode of delivering combination therapy to improve glycemic control. Alogliptin has been studied clinically as initial therapy in treatment-naïve patients with T2DM and as initial therapy or add-on in combination with other antidiabetic agents. Clinical trial data with alogliptin demonstrate clinical efficacy in terms of glycosylated hemoglobin A1c and fasting plasma glucose reductions when used both as monotherapy and as a component of two- or three-drug combination regimens for the treatment of T2DM. Extensive Phase II and Phase III clinical trial data support the use of alogliptin in combination with metformin and pioglitazone. Glycemic reduction with both combinations is similar to the sum of the respective monotherapies, with adverse event rates similar – or more moderate – than those observed with up-titration of monotherapy or the addition of other antihyperglycemic agents.Keywords: antidiabetic, diabetes management, DPP-4 inhibitor, fixed-dose combination, incretin therapyHollDQNeumiller JJDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2014, Iss default, Pp 277-288 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Specialties of internal medicine RC581-951
spellingShingle	Specialties of internal medicine RC581-951 Holl DQ Neumiller JJ Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
description	Daniel Q Holland, Joshua J NeumillerDepartment of Pharmacotherapy, College of Pharmacy, Washington State University, Spokane, Washington, USAAbstract: Alogliptin is a selective dipeptidyl peptidase-4 inhibitor recently marketed for once-daily administration in the treatment of type 2 diabetes mellitus (T2DM). Fixed-dose combinations of alogliptin with both metformin and pioglitazone are also commercially available, providing a measure of convenience in addition to an effective mode of delivering combination therapy to improve glycemic control. Alogliptin has been studied clinically as initial therapy in treatment-naïve patients with T2DM and as initial therapy or add-on in combination with other antidiabetic agents. Clinical trial data with alogliptin demonstrate clinical efficacy in terms of glycosylated hemoglobin A1c and fasting plasma glucose reductions when used both as monotherapy and as a component of two- or three-drug combination regimens for the treatment of T2DM. Extensive Phase II and Phase III clinical trial data support the use of alogliptin in combination with metformin and pioglitazone. Glycemic reduction with both combinations is similar to the sum of the respective monotherapies, with adverse event rates similar – or more moderate – than those observed with up-titration of monotherapy or the addition of other antihyperglycemic agents.Keywords: antidiabetic, diabetes management, DPP-4 inhibitor, fixed-dose combination, incretin therapy
format	article
author	Holl DQ Neumiller JJ
author_facet	Holl DQ Neumiller JJ
author_sort	Holl
title	Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
title_short	Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
title_full	Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
title_fullStr	Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
title_full_unstemmed	Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
title_sort	alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/53402642e95245d494c8940a9115b18a
work_keys_str_mv	AT holl alogliptinincombinationwithmetforminandpioglitazoneforthetreatmentoftype2diabetesmellitus AT dq alogliptinincombinationwithmetforminandpioglitazoneforthetreatmentoftype2diabetesmellitus AT neumillerjj alogliptinincombinationwithmetforminandpioglitazoneforthetreatmentoftype2diabetesmellitus
_version_	1718401365923856384

Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus

Ejemplares similares